CAMBRIDGE, Mass., June 8 /PRNewswire-FirstCall/ -- Advanced Magnetics, Inc. today announced that it will participate in the Needham & Company Biotech and Medical Conference being held June 14, 2007 at the New York Palace Hotel. Brian J.G. Pereira, MD, President and CEO of Advanced Magnetics, will present an overview of the company at 1:00 pm ET.
A live webcast of this presentation will be accessible through the Investors section of the company's website at http://www.advancedmagnetics.com . Following the conference, the webcast will be archived on the Advanced Magnetics website until July 13, 2007.
About Advanced Magnetics
Advanced Magnetics, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease. The company has completed enrollment in four Phase III clinical trials with ferumoxytol and has presented data on three of the four trials.
Combidex, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
The company has two commercial products, Feridex I.V.(R) and GastroMARK(R), both of which are imaging agents that are approved and marketed in the United States, Europe and other countries.
Senior Director, Investor Relations
Advanced Magnetics, Inc.
CONTACT: Kristen Galfetti, Senior Director, Investor Relations of AdvancedMagnetics, Inc., +1-617-498-3362, email@example.com